HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFF first quarter

This article was originally published in The Rose Sheet

Executive Summary

North American functional fragrance sales rose 20% in Q1 based on "new wins," but 20% decline in fine fragrance revenues led to flat fragrance performance overall for the region, excluding businesses divested in 2001, Chief Financial Officer Doug Wetmore states during April 25 financial report. European fragrance sales declined 1% in dollar terms, pulled down by high single-digit decrease in fine fragrances. Worldwide fragrance sales off 3% during quarter on pro forma basis, excluding businesses sold in late 2001 and reflecting new accounting rules for goodwill and intangibles, according to firm's April 25 1sales and earnings release. Consolidated sales of $445.8 mil. for Q1 were down 3.9% on pro forma basis. Net earnings doubled to $41.9 mil., up from $20.3 mil. in previous-year period...

You may also be interested in...



Data For Two HER2-Positive Breast Cancer Drugs Impress, Including On Overall Survival

AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.

The FDA Builds On Lessons Learned In Rebuilding Quality Metrics Program

US FDA officials tell industry that implementing a quality metrics program is an agency priority and that a rejiggered program will incorporate various elements of other quality metrics initiatives being piloted by the agency, industry and academia.

Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026

Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.

UsernamePublicRestriction

Register

RS010240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel